OBJECTIVES: This retrospective study evaluated the outcomes of patients who underwent unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with different types of drug-eluting stents (DES). BACKGROUND: The standard of care for patients with ULMCA is coronary artery bypass surgery. However, current guidelines recommend PCI in clinical conditions where there is an increased risk of adverse surgical outcomes. Clinical outcomes of patients undergoing ULMCA PCI with different types of drug-eluting stents (DES) are unknown. METHODS: Data from a multicenter international registry, which included 239 consecutive patients from four institutions who ULMCA PCI with DES, were collected. RESULTS: There were 42 patients receiving paclitaxel-eluting stent (PES), 158 patients receiving sirolimus-eluting stent (SES), and 39 patients receiving everolimus-eluting stent (EES). There was no statistical difference in major adverse cardiovascular events, cardiac death, myocardial infarction, target lesion revascularization, and stent thrombosis among PES, SES, and EES at 30 days and 1 year. CONCLUSIONS: There are no differences in clinical events among patients receiving PES, SES, and EES for ULMCA disease.
OBJECTIVES: This retrospective study evaluated the outcomes of patients who underwent unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with different types of drug-eluting stents (DES). BACKGROUND: The standard of care for patients with ULMCA is coronary artery bypass surgery. However, current guidelines recommend PCI in clinical conditions where there is an increased risk of adverse surgical outcomes. Clinical outcomes of patients undergoing ULMCA PCI with different types of drug-eluting stents (DES) are unknown. METHODS: Data from a multicenter international registry, which included 239 consecutive patients from four institutions who ULMCA PCI with DES, were collected. RESULTS: There were 42 patients receiving paclitaxel-eluting stent (PES), 158 patients receiving sirolimus-eluting stent (SES), and 39 patients receiving everolimus-eluting stent (EES). There was no statistical difference in major adverse cardiovascular events, cardiac death, myocardial infarction, target lesion revascularization, and stent thrombosis among PES, SES, and EES at 30 days and 1 year. CONCLUSIONS: There are no differences in clinical events among patients receiving PES, SES, and EES for ULMCA disease.
Entities:
Keywords:
Drug-eluting stent; Left main disease; Percutaneous coronary intervention
Authors: Laura Mauri; E John Orav; A James O'Malley; Jeffrey W Moses; Martin B Leon; David R Holmes; Paul S Teirstein; Joachim Schofer; Günter Breithardt; Donald E Cutlip; Dean J Kereiakes; Chunxue Shi; Brian G Firth; Dennis J Donohoe; Richard E Kuntz Journal: Circulation Date: 2005-01-17 Impact factor: 29.690
Authors: Frederick G Kushner; Mary Hand; Sidney C Smith; Spencer B King; Jeffrey L Anderson; Elliott M Antman; Steven R Bailey; Eric R Bates; James C Blankenship; Donald E Casey; Lee A Green; Judith S Hochman; Alice K Jacobs; Harlan M Krumholz; Douglass A Morrison; Joseph P Ornato; David L Pearle; Eric D Peterson; Michael A Sloan; Patrick L Whitlow; David O Williams Journal: J Am Coll Cardiol Date: 2009-12-01 Impact factor: 24.094
Authors: Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr Journal: N Engl J Med Date: 2009-02-18 Impact factor: 91.245
Authors: Gregg W Stone; Mark Midei; William Newman; Mark Sanz; James B Hermiller; Jerome Williams; Naim Farhat; Kenneth W Mahaffey; Donald E Cutlip; Peter J Fitzgerald; Poornima Sood; Xiaolu Su; Alexandra J Lansky Journal: JAMA Date: 2008-04-23 Impact factor: 56.272
Authors: Christoph Stettler; Simon Wandel; Sabin Allemann; Adnan Kastrati; Marie Claude Morice; Albert Schömig; Matthias E Pfisterer; Gregg W Stone; Martin B Leon; José Suarez de Lezo; Jean-Jacques Goy; Seung-Jung Park; Manel Sabaté; Maarten J Suttorp; Henning Kelbaek; Christian Spaulding; Maurizio Menichelli; Paul Vermeersch; Maurits T Dirksen; Pavel Cervinka; Anna Sonia Petronio; Alain J Nordmann; Peter Diem; Bernhard Meier; Marcel Zwahlen; Stephan Reichenbach; Sven Trelle; Stephan Windecker; Peter Jüni Journal: Lancet Date: 2007-09-15 Impact factor: 79.321
Authors: Dena M Bravata; Allison L Gienger; Kathryn M McDonald; Vandana Sundaram; Marco V Perez; Robin Varghese; John R Kapoor; Reza Ardehali; Douglas K Owens; Mark A Hlatky Journal: Ann Intern Med Date: 2007-10-15 Impact factor: 25.391